<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140604</url>
  </required_header>
  <id_info>
    <org_study_id>GLA-001</org_study_id>
    <nct_id>NCT04140604</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Lactobacillus Salivarius AP-32 and Bifidobacterium Lactis CP-9 in Healthy Infants.</brief_title>
  <official_title>A Three-arm, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Lactobacillus Salivarius AP-32 and Bifidobacterium Lactis CP-9 Used Individually in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hsieh-Hsun Ho</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glac Biotech Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a three-arm, double-blind, placebo-controlled study to investigate the safety of L.&#xD;
      salivarius AP-32 and B. lactis CP-9 used individually in healthy infants.&#xD;
&#xD;
      Infants will be given the content of one capsule (mixed in infant formula or breast milk)&#xD;
      twice daily (morning and evening) for 15 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a three-arm, double-blind, placebo-controlled study to investigate the safety of L.&#xD;
      salivarius AP-32 and B. lactis CP-9 used individually in healthy infants.&#xD;
&#xD;
      Infants will be given the content of one capsule (mixed in infant formula or breast milk)&#xD;
      twice daily (morning and evening) for 15 weeks. Follow-up visits will take place at study&#xD;
      days 14±3, 42±3, 70±4 and 105±4.&#xD;
&#xD;
      Caregivers will keep a diary of the volume of formula intake/minutes of breastfeeding, stool&#xD;
      frequency and consistency (hard, formed, soft/paste or loose/watery), symptoms of digestive&#xD;
      tolerance (regurgitation and flatulence), sleeping time, crying/fussing time and episodes for&#xD;
      3 days before each visit. At each visit, the research team will review the diary and conduct&#xD;
      physical examination, including anthropometric measurements (weight, recumbent length, and&#xD;
      head circumference).&#xD;
&#xD;
      Fecal samples will be collected prior to the first administration of the assigned study&#xD;
      product and at the end of study for microbiota analysis.&#xD;
&#xD;
      Adverse events (AEs) will be assessed based on inquires to the caregivers. AEs will be&#xD;
      classified as related or unrelated based on a relationship to study product intake according&#xD;
      to the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">April 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Active:&#xD;
L. salivarius AP-32&#xD;
B. lactis CP-9 supplied as 0.5 g capsules.&#xD;
Placebo:&#xD;
The placebo capsules are identical to the L. salivarius AP-32 and B. lactis CP-9 capsules except for the probiotics.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double-blind study so neither investigator and site staff, nor the subject know which treatment has been assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean weight gain.</measure>
    <time_frame>15 weeks.</time_frame>
    <description>The change value from baseline at the end of the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events (AEs).</measure>
    <time_frame>15 weeks.</time_frame>
    <description>The occurrence of adverse events (AEs) during the period of probiotic or placebo intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurements of recumbent length.</measure>
    <time_frame>15 weeks.</time_frame>
    <description>The change value from baseline at the end of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurements of head circumference.</measure>
    <time_frame>15 weeks.</time_frame>
    <description>The change value from baseline at the end of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of regurgitation.</measure>
    <time_frame>15 weeks.</time_frame>
    <description>Caregivers will be instructed by the investigator or the designated study center personnel to record the regurgitation for three days within the week before each study visit. At each study visit, the investigator or the designated study center personnel will review the diary and record the times of regurgitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of flatulence.</measure>
    <time_frame>15 weeks.</time_frame>
    <description>Caregivers will be instructed by the investigator or the designated study center personnel to record the flatulence for three days within the week before each study visit. At each study visit, the investigator or the designated study center personnel will review the diary and record the times of flatulence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious diseases.</measure>
    <time_frame>15 weeks.</time_frame>
    <description>Observing the incidence of infectious diseases during the period of probiotic or placebo intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of allergic diseases.</measure>
    <time_frame>15 weeks.</time_frame>
    <description>Observing the incidence of allergic diseases during the period of probiotic or placebo intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crying and/or fussing time (hours/day) and episodes.</measure>
    <time_frame>15 weeks.</time_frame>
    <description>Observing the crying and/or fussing time (hours/day) and episodes during the period of probiotic or placebo intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>The Safety of Lactobacillus Salivarius AP-32</condition>
  <condition>The Safety of Bifidobacterium Lactis CP-9</condition>
  <arm_group>
    <arm_group_label>Lactobacillus salivarius AP-32</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP-32 is a 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Lactobacillus salivarius subsp. salicinius AP-32 and maltodextrin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacterium lactis CP-9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP-9 is a 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Bifidobacterium animalis subsp. lactis CP-9 and maltodextrin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules are identical to the L. salivarius AP-32 and B. lactis CP-9 capsules except for the probiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactobacillus salivarius AP-32</intervention_name>
    <description>Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.</description>
    <arm_group_label>Lactobacillus salivarius AP-32</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bifidobacterium lactis CP-9</intervention_name>
    <description>Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.</description>
    <arm_group_label>Bifidobacterium lactis CP-9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having informed consent of the parent or legal guardian.&#xD;
&#xD;
          -  Healthy male and female infants between 7 days and 2 months (60 ± 2 days) of age at&#xD;
             the time of study initiation.&#xD;
&#xD;
          -  Full term ( ≧ 36 weeks gestation at birth).&#xD;
&#xD;
          -  Birth weight ≧ 2500 g.&#xD;
&#xD;
          -  Able and willing to comply with all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to thrive (weight gain &lt; 100 grams/week average from birth to the last&#xD;
             recorded weight).&#xD;
&#xD;
          -  Major acute or chronic illness (e.g. significant cardiac, respiratory, hematological,&#xD;
             gastrointestinal or other systemic diseases, major developmental or genetic&#xD;
             abnormality).&#xD;
&#xD;
          -  Use of substances that alter gut microbiota (antibiotics, prebiotics, probiotics or&#xD;
             gastric acid inhibitors) within 2 weeks prior to the study initiation.&#xD;
&#xD;
          -  For breastfed infants, use of antibiotics, prebiotics and probiotics by the mothers.&#xD;
&#xD;
          -  Cow's milk protein allergy.&#xD;
&#xD;
          -  Feeding difficulties.&#xD;
&#xD;
          -  History of any allergies to maltodextrin.&#xD;
&#xD;
          -  Participation in another clinical trial.&#xD;
&#xD;
          -  Any other clinically significant medical, psychiatric and/or social reason as&#xD;
             determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsieh-Hsun Ho, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glac Biotech Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng-Hsun Chiu, M.D.,Ph.D</last_name>
    <phone>+886+3+3281200</phone>
    <phone_ext>8284</phone_ext>
    <email>chchiu@adm.cgmh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hsieh-Hsun Ho, Ph.D</last_name>
    <phone>+886+6+5891876</phone>
    <phone_ext>230</phone_ext>
    <email>sam.ho@glact.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Glac Biotech Co., Ltd</name>
      <address>
        <city>Tainan City</city>
        <zip>802</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsieh-Hsun Ho, Ph. D</last_name>
      <phone>+886+6+5891876</phone>
      <phone_ext>230</phone_ext>
      <email>sam.ho@glact.com.tw</email>
    </contact>
    <contact_backup>
      <last_name>Yi-Wei Kuo, Master</last_name>
      <phone>+886+6+5891876</phone>
      <phone_ext>231</phone_ext>
      <email>vic.kuo@glact.com.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Hsieh-Hsun Ho, Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Glac Biotech Co., Ltd</investigator_affiliation>
    <investigator_full_name>Hsieh-Hsun Ho</investigator_full_name>
    <investigator_title>R.D. Manager Doctor</investigator_title>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Lactobacillus salivarius AP-32</keyword>
  <keyword>Bifidobacterium lactis CP-9</keyword>
  <keyword>Safety</keyword>
  <keyword>Healthy infant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

